Acrivon Therapeutics Q3 EPS $(0.42) Beats $(0.46) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 10.64 percent increase over losses of $(0.47) per share
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 10.64 percent increase over losses of $(0.47) per share from the same period last year.
